Is Ocugen, Inc. overvalued or undervalued?

As of 9 February 2024, Ocugen, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently assessed as overvalued, given its significant negative financial metrics. Notable ratios include a Price to Book Value of 19.46, an EV to EBIT of -5.26, and an EV to EBITDA of -5.53, all indicating substantial financial distress.
In comparison to its peers, Ocugen's valuation stands out unfavorably. For instance, Talaris Therapeutics, Inc. has an EV to EBITDA of -2.2059, while Esperion Therapeutics, Inc. also carries a risky designation with an EV to EBITDA of -17.4452. The stark contrast in these ratios highlights Ocugen's precarious position within the industry. Despite a year-to-date return of 21.88%, the overall trend shows a decline of 26.23% over the past year, further reinforcing the notion that the stock is overvalued relative to its financial performance.